Prasugrel hydrochloride
Modify Date: 2024-01-02 20:43:15
Prasugrel hydrochloride structure
|
Common Name | Prasugrel hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 389574-19-0 | Molecular Weight | 409.902 | |
| Density | N/A | Boiling Point | 493.5ºC at 760 mmHg | |
| Molecular Formula | C20H21ClFNO3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 252.3℃ | |
Use of Prasugrel hydrochloridePrasugrel hydrochloride is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel hydrochloride is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel hydrochloride reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel hydrochloride AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis |
| Name | [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Prasugrel hydrochloride is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel hydrochloride is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel hydrochloride reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel hydrochloride AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis |
|---|---|
| Related Catalog | |
| References |
| Boiling Point | 493.5ºC at 760 mmHg |
|---|---|
| Molecular Formula | C20H21ClFNO3S |
| Molecular Weight | 409.902 |
| Flash Point | 252.3℃ |
| Exact Mass | 409.091461 |
| PSA | 74.85000 |
| LogP | 4.63090 |
| Storage condition | -20℃ |
| 5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride (1:1) |
| Prasugrel hydrochloride |
| Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (1:1) |
| Prasugrel0 Hydrochloriden(Discontinued) |
| Prasugren hydrochloride |
| Prasugrelhydrochloride |
| Efient |
| Prasugrel (hydrochloride) |